“Rehabilitación del grupo electrógeno de la Universidad Técnica de Cotopaxi Extensión La Maná en el bloque A”.

The present investigation was developed at Universidad Técnica de Cotopaxi in La Maná block "A", with the purpose of diagnosing the required power, through electrical consumption and maximum unit demand, through the collection of data from all electrical equipment installed in the different sectors from the ground floor to the top floor, in which the amount of total equipment was obtained and the power was obtained through the characteristic plate in various places such as doctor's office, secretary, library, offices, classrooms, laboratories, etc. The importance of the study lies in the activities carried out to determine if the inactive generator set in the UTC building still had the capacity to generate electricity to supply all sectors during a conventional power failure or outage. For the complete and functional rehabilitation of the generator set, mechanical and electronic maintenance activities and adaptation of the area where it is installed were carried out, successfully achieving its total rehabilitation.La presente investigación se desarrolló en la Universidad Técnica de Cotopaxi Extensión La Maná bloque “A”, con el propósito de diagnosticar la potencia requerida, mediante el consumo eléctrico y la demanda máxima unitaria, a través de la recolección de da tos de todos los equipos eléctricos instalados en los diferentes sectores desde la planta baja hasta el último piso, en la cual se obtuvo la cantidad de equipos totales y la potencia se obtuvo a través de la placa característica en varios sitios como es: c consultorio médico, secretaria, biblioteca, oficinas, aulas, laboratorios etc. La importancia del estudio recae en las actividades realizadas para determinar si el grupo electrógeno inactivo en el edificio de la UTC, contaba todavía con la capacidad de generación de energía eléctrica para suministrar a todos los sectores durante un fallo o corte eléctrico convencional. Para la rehabilitación del grupo electrógeno completa y funcional se realizó actividades de mantenimiento mecánico, electrónico y adecuación del área donde se encuentra instalado, logrando con éxito su total rehabilitación

Differential MIR-21 expression in plasma from mesenteric versus peripheral veins: an observational study of disease-free survival in surgically resected colon cancer patients.

Findings on the role of plasma miR-21 expression in colorectal cancer are contradictory. Before reaching a peripheral vein (PV), microRNAs released by the tumor are dispersed throughout the body. We hypothesized that blood drawn from the mesenteric vein (MV) near the site of the primary tumor could provide more homogeneous information than blood drawn from the PV.We have analyzed miR-21 expression in matched samples of tumor tissue, normal tissue, MV plasma, and PV plasma in 57 surgically resected patients with colon cancer and correlated our findings with clinical characteristics and disease-free survival (DFS).miR-21 expression was higher in MV than PV plasma (P = 0.014) and in tumor than in normal tissue (P < 0.001). Patients with high levels of miR-21 in MV plasma had shorter DFS (P = 0.05) than those with low levels, and those with high levels in both MV and PV plasma had shorter DFS than all other patients (P = 0.01).Our findings suggest that the primary tumor in colon cancer releases high concentrations of miR-21 in the MV but that these concentrations are later diluted in the circulatory system. MV expression of miR-21 may be a stronger prognostic marker than PV expression

Second-line treatment in advanced gastric cancer : Data from the Spanish AGAMENON registry

Second-line treatments boost overall survival in advanced gastric cancer (AGC). However, there is a paucity of information as to patterns of use and the results achieved in actual clinical practice. The study population comprised patients with AGC in the AGAMENON registry who had received second-line. The objective was to describe the pattern of second-line therapies administered, progression-free survival following second-line (PFS-2), and post-progression survival since first-line (PPS). 2311 cases with 2066 progression events since first-line (89.3%) were recorded; 245 (10.6%) patients died during first-line treatment and 1326/2066 (64.1%) received a second-line. Median PFS-2 and PPS were 3.1 (95% CI, 2.9-3.3) and 5.8 months (5.5-6.3), respectively. The most widely used strategies were monoCT (56.9%), polyCT (15.0%), ramucirumab+CT (12.6%), platinum-reintroduction (8.3%), trastuzumab+CT (6.1%), and ramucirumab (1.1%). PFS-2/PPS medians gradually increased in monoCT, 2.6/5.1 months; polyCT 3.4/6.3 months; ramucirumab+CT, 4.1/6.5 months; platinum-reintroduction, 4.2/6.7 months, and for the HER2+ subgroup in particular, trastuzumab+CT, 5.2/11.7 months. Correlation between PFS since first-line and OS was moderate in the series as a whole (Kendall's τ = 0.613), lower in those subjects who received second-line (Kendall's τ = 0.539), especially with ramucirumab+CT (Kendall's τ = 0.413). This analysis reveals the diversity in second-line treatment for AGC, highlighting the effectiveness of paclitaxel-ramucirumab and, for a selected subgroup of patients, platinum reintroduction; both strategies endorsed by recent clinical guidelines

Turismo y Género. Una mirada desde Iberoamérica

En las últimas cuatro décadas ha crecido el interés de la academia, gobiernos y organizaciones internacionales por estudiar cómo ha sido, en qué circunstancias y qué efectos ha traído la incorporación de las mujeres al turismo. De esta forma se inicia un debate internacional en el que se cuestionan, por un lado, los efectos negativos de esta actividad en la vida de las mujeres y, por el otro, se realzan beneficios económicos que mejoran su calidad de vida y la de sus familias. A pesar del interés y la importante participación de mujeres en el sector turístico, aún son insuficientes los estudios enfocados en explicar y evidenciar su situación laboral. En este contexto, surge la idea de publicar un libro que compilara trabajos recientes en torno a las condiciones de las trabajadoras en el sector turístico de Iberoamérica.Esta obra se compone de tres secciones, Aproximaciones teórico metodológicas, Mujer y turismo en zonas rurales y La mujer en empresas turísticas, cuyas investigaciones abordan distintos temas para evidenciar los problemas enfrentados por las mujeres, proponer diversas soluciones y comprender su escenario laboral. En la primera sección, hay dos capítulos que proponen marcos teóricos para analizar el empoderamiento de las mujeres en el turismo rural. Los resultados de investigaciones de la segunda sección visibilizan las desigualdades, reflexionan y proponen acciones para mejorar las condiciones de las trabajadoras turísticas. En la última, en los tres capítulos, concentrados en las actividades empresariales, se estudian las desventajas y obstáculos de la empleada en alguna compañía turística.Universidad Autónoma del Estado de México

External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack of phase III trials, many clinicians administer trastuzumab with alternative regimens. One meta-analysis suggests that substituting cisplatin for oxaliplatin might lead to greater efficacy and less toxicity. Methods: 594 patients with HER2-positive gastroesophageal adenocarcinoma were recruited from the AGAMENON-SEOM registry. The objective was to evaluate the external validity of clinical trials with chemotherapy and trastuzumab. Results: The regimens used in at least 5% of the patients were XP (27%), oxaliplatin and capecitabine (CAPOX) (26%), oxaliplatin and 5-fluorouracil (FOLFOX) (14%), FP (14%), triplet with anthracycline/docetaxel (7%), and carboplatin-FU (5%). Median exposure to trastuzumab was longer with FOLFOX (11.4 months, 95% CI, 9.1-21.0) versus ToGA regimens (7.5, 6.4-8.5), p < 0.001. Patients with HER2-IHC 3+ cancers had higher response rates than those with IHC 2+/FISH+, odds-ratio 1.97 (95% CI, 1.25-3.09). The results achieved with CAPOX-trastuzumab were comparable to those attained with ToGA regimens. FOLFOX-trastuzumab was superior to ToGA schemes in terms of overall survival (OS), with a greater magnitude of effect in IHC 2+/FISH+ tumors (HR 0.47, 0.24-0.92) compared with IHC 3+ (HR 0.69, 0.49-0.96), and in diffuse (HR 0.37, 0.20-0.69) versus intestinal-type tumors (HR 0.76, 0.54-1.06). Conclusion: We have updated the external validity of clinical trials with trastuzumab in first-line treatment of gastric cancer. Our data confirm the comparable outcomes of ToGA regimens and CAPOX-trastuzumab in clinical practice and point toward a possible benefit of FOLFOX-trastuzumab, contingent on the subtypes typically less sensitive to trastuzumab, to be confirmed in clinical trials

Metabolite and lipoprotein profiles reveal sex-related oxidative stress imbalance in de novo drug-naive Parkinson's disease patients

Parkinson's disease (PD) is the neurological disorder showing the greatest rise in prevalence from 1990 to 2016. Despite clinical definition criteria and a tremendous effort to develop objective biomarkers, precise diagnosis of PD is still unavailable at early stage. In recent years, an increasing number of studies have used omic methods to unveil the molecular basis of PD, providing a detailed characterization of potentially pathological alterations in various biological specimens. Metabolomics could provide useful insights to deepen our knowledge of PD aetiopathogenesis, to identify signatures that distinguish groups of patients and uncover responsive biomarkers of PD that may be significant in early detection and in tracking the disease progression and drug treatment efficacy. The present work is the first large metabolomic study based on nuclear magnetic resonance (NMR) with an independent validation cohort aiming at the serum characterization of de novo drug-naive PD patients. Here, NMR is applied to sera from large training and independent validation cohorts of German subjects. Multivariate and univariate approaches are used to infer metabolic differences that characterize the metabolite and the lipoprotein profiles of newly diagnosed de novo drug-naive PD patients also in relation to the biological sex of the subjects in the study, evidencing a more pronounced fingerprint of the pathology in male patients. The presence of a validation cohort allowed us to confirm altered levels of acetone and cholesterol in male PD patients. By comparing the metabolites and lipoproteins levels among de novo drug-naive PD patients, age- and sex-matched healthy controls, and a group of advanced PD patients, we detected several descriptors of stronger oxidative stress

Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients

Abstract: A prodromal phase of Parkinson’s disease (PD) may precede motor manifestations by decades. PD patients’ siblings are at higher risk for PD, but the prevalence and distribution of prodromal symptoms are unknown. The study objectives were (1) to assess motor and non-motor features estimating prodromal PD probability in PD siblings recruited within the European PROPAG-AGEING project; (2) to compare motor and non-motor symptoms to the well-established DeNoPa cohort. 340 PD siblings from three sites (Bologna, Seville, Kassel/Goettingen) underwent clinical and neurological evaluations of PD markers. The German part of the cohort was compared with German de novo PD patients (dnPDs) and healthy controls (CTRs) from DeNoPa. Fifteen (4.4%) siblings presented with subtle signs of motor impairment, with MDS-UPDRS-III scores not clinically different from CTRs. Symptoms of orthostatic hypotension were present in 47 siblings (13.8%), no different to CTRs (p = 0.072). No differences were found for olfaction and overall cognition; German-siblings performed worse than CTRs in visuospatial-executive and language tasks. 3/147 siblings had video-polysomnography-confirmed REM sleep behavior disorder (RBD), none was positive on the RBD Screening Questionnaire. 173/300 siblings had <1% probability of having prodromal PD; 100 between 1 and 10%, 26 siblings between 10 and 80%, one fulfilled the criteria for prodromal PD. According to the current analysis, we cannot confirm the increased risk of PD siblings for prodromal PD. Siblings showed a heterogeneous distribution of prodromal PD markers and probability. Additional parameters, including strong disease markers, should be investigated to verify if these results depend on validity and sensitivity of prodromal PD criteria, or if siblings’ risk is not elevated

Estudio de la supervivencia global y de los factores pronósticos del cáncer gástrico localizado tratado de forma radical en el Hospital Parc Taulí de Sabadell entre los años 2004 y 2020

Estudi observacional, unicèntric, retrospectiu dels pacients afectes de càncer gàstric no metastàtic, tractats amb intenció radical a l'Hospital Parc Taulí de Sabadell des del 01 de gener de 2004 fins al 31 de desembre de 2020. S'hi van incloure un total de 266 pacients, intervinguts de manera radical. L'objectiu principal va ser determinar la supervivència global i la supervivència lliure de malaltia. Els objectius secundaris, determinar la morbiditat i mortalitat quirúrgica, l'efecte de la cirurgia radical, tipus de limfadenectomia, localització del tumor, el valor pronòstic del sexe, l'edat al diagnòstic i les característiques patològiques del tumor (classificació de Lauren, grau histològic, invasió perineural i vasculolinfàtica) en la supervivència global i en la supervivència lliure de malaltia, a més de l'efecte dels tractaments complementaris realitzats (QT adjuvant, QTRT adjuvant i QT perioperatòria).Estudio observacional, unicéntrico, retrospectivo de los pacientes afectos de cáncer gástrico no metastásico, tratados con intención radical en el Hospital Parc Taulí de Sabadell desde el 01 de enero de 2004 hasta el 31 de diciembre de 2020. Se incluyeron un total de 266 pacientes, intervenidos de manera radical. El objetivo principal fue determinar la supervivencia global (SG) y la supervivencia libre de enfermedad (SLE). Los objetivos secundarios, determinar la morbilidad y la mortalidad quirúrgica, el efecto de la cirugía radical, tipo de linfadenectomía, localización del tumor, el valor pronóstico del sexo, la edad al diagnóstico y las características patológicas del tumor (clasificación de Lauren, grado histológico, invasión perineural y vasculolinfática) en la SG y en la SLE, además del efecto de los tratamientos complementarios realizados (QT adyuvante, QTRT adyuvante y QT perioperatoria).This is a retrospective, single-center, observational study of patients with non-metastatic gastric cancer who underwent radical treatment at the Parc Taulí Hospital in Sabadell from January 1st, 2004 to December 31st, 2020. A total of 266 patients who underwent radical surgery were included. The primary objective was to determine overall survival (OS) and disease-free survival (DFS). Secondary objectives included determining surgical morbidity and mortality, the effect of radical surgery, type of lymphadenectomy, tumor location, prognostic value of sex, age at diagnosis, and pathological characteristics of the tumor (Lauren classification, histological grade, perineural and vasculolymphatic invasion) on OS and DFS, as well as the effect of adjuvant treatments (adjuvant chemotherapy, adjuvant chemoradiotherapy, and perioperative chemotherapy).Universitat Autònoma de Barcelona. Programa de Doctorat en Medicin

Estudio de la supervivencia global y de los factores pronósticos del cáncer gástrico localizado tratado de forma radical en el Hospital Parc Taulí de Sabadell entre los años 2004 y 2020

Estudi observacional, unicèntric, retrospectiu dels pacients afectes de càncer gàstric no metastàtic, tractats amb intenció radical a l'Hospital Parc Taulí de Sabadell des del 01 de gener de 2004 fins al 31 de desembre de 2020. S'hi van incloure un total de 266 pacients, intervinguts de manera radical. L'objectiu principal va ser determinar la supervivència global i la supervivència lliure de malaltia. Els objectius secundaris, determinar la morbiditat i mortalitat quirúrgica, l'efecte de la cirurgia radical, tipus de limfadenectomia, localització del tumor, el valor pronòstic del sexe, l'edat al diagnòstic i les característiques patològiques del tumor (classificació de Lauren, grau histològic, invasió perineural i vasculolinfàtica) en la supervivència global i en la supervivència lliure de malaltia, a més de l'efecte dels tractaments complementaris realitzats (QT adjuvant, QTRT adjuvant i QT perioperatòria).Estudio observacional, unicéntrico, retrospectivo de los pacientes afectos de cáncer gástrico no metastásico, tratados con intención radical en el Hospital Parc Taulí de Sabadell desde el 01 de enero de 2004 hasta el 31 de diciembre de 2020. Se incluyeron un total de 266 pacientes, intervenidos de manera radical. El objetivo principal fue determinar la supervivencia global (SG) y la supervivencia libre de enfermedad (SLE). Los objetivos secundarios, determinar la morbilidad y la mortalidad quirúrgica, el efecto de la cirugía radical, tipo de linfadenectomía, localización del tumor, el valor pronóstico del sexo, la edad al diagnóstico y las características patológicas del tumor (clasificación de Lauren, grado histológico, invasión perineural y vasculolinfática) en la SG y en la SLE, además del efecto de los tratamientos complementarios realizados (QT adyuvante, QTRT adyuvante y QT perioperatoria).This is a retrospective, single-center, observational study of patients with non-metastatic gastric cancer who underwent radical treatment at the Parc Taulí Hospital in Sabadell from January 1st, 2004 to December 31st, 2020. A total of 266 patients who underwent radical surgery were included. The primary objective was to determine overall survival (OS) and disease-free survival (DFS). Secondary objectives included determining surgical morbidity and mortality, the effect of radical surgery, type of lymphadenectomy, tumor location, prognostic value of sex, age at diagnosis, and pathological characteristics of the tumor (Lauren classification, histological grade, perineural and vasculolymphatic invasion) on OS and DFS, as well as the effect of adjuvant treatments (adjuvant chemotherapy, adjuvant chemoradiotherapy, and perioperative chemotherapy)